The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study
| Autor: | Mortimer, Kevin, Lesosky, Maia, García-Marcos, Luis, Innes Asher, M, Pearce, Neil, Ellwood, Eamon, Bissell, Karen, El Sony, Asma, Ellwood, Philippa, Marks, Guy B, Martínez-Torres, Antonela, Morales, Eva, Perez-Fernandez, Virginia, Robertson, Steven, Rutter, Charlotte E, Silverwood, Richard J, Strachan, David P, Chiang, Chen-Yuan, Global Asthma Network Phase I Study Group |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| ISSN: | 1399-3003 0903-1936 |
| Popis: | Asthma, hay fever and eczema are three common chronic conditions. There are no recent multi-country data on the burden of these three conditions in adults; the aims of this study are to fill this evidence gap.The Global Asthma Network (GAN) Phase I is a multi-country cross-sectional population-based study using the same core methodology as the International Study of Asthma and Allergies in Childhood (ISAAC) Phase III. It provides data on the burden of asthma, hay fever, and eczema not only in children and adolescents but also for the first time in their parents/guardians.Data were available from 193 912 adults (104 061 female; mean age 38 (sd 7.5)) in 43 centres in 17 countries. The overall prevalences (range) of symptoms of current wheeze, asthma ever, hay fever ever and eczema ever were 6.6% (0.9%-32.7%), 4.4%(0.9%-29.0%), 14.4%(2.8%-45.7%), and 9.9%(1.6%-29.5%), respectively. Centre prevalence varied considerably both between countries and within countries. There was a moderate correlation between hay fever ever and asthma ever, and between eczema ever and hay fever ever at the centre level. There were moderate to strong correlations between indicators of the burden of disease reported in adults and the two younger age groups.We found evidence for a substantial burden of asthma, hay fever ever and eczema ever in countries examined highlighting the major public health importance of these diseases. Prevention strategies and equitable access to effective and affordable treatments for these three conditions would help mitigate the avoidable morbidity they cause. [Abstract copyright: Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|